Form D · Biotechnology

Magnolia Neurosciences Corp

New York, NY · CIK 0001749206

Offering snapshot reported Nov 23, 2021 · SEC filing

Reported sold: $18.4M
Investors reported: 9
Minimum accepted: $0
First sale: Jul 7, 2020

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$5,000,000 → $18,393,417
Reported investors8 → 9

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Nov 23, 2021	Amendment	$18,393,417	$13,393,417vs Jul 22, 2020	9	SEC filing
Jul 22, 2020	Initial	$5,000,000	No comparison	8	SEC filing
Aug 17, 2018	Initial	$8,000,000	No comparison	11	SEC filing

Offering details

Securities: Equity
Exemptions: 06b
Duration over one year: Yes
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-371555

Source: Form D, filed Nov 23, 2021. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Michael Baran	Director
Margarita Chavez	Director
Barbara Dalton	Director
M. Johnston Erwin	Director
Steve Gillis	Director
Ian Howes	Executive
Thong Le	Director, Executive
Alice Ly	Director
Joel Marcus	Director
Kendall Mohler	Executive
David Schubert	Executive
Asish Xavier	Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:

430 East 29 Th Street Suite 840
New York, NY, 10016